Core Insights - Techne (TECH) reported revenue of $286.56 million for the quarter ended September 2025, reflecting a year-over-year decline of 1% and a surprise of -0.96% compared to the Zacks Consensus Estimate of $289.34 million [1] - The earnings per share (EPS) for the same period was $0.42, unchanged from the previous year, indicating no EPS surprise against the consensus estimate [1] Financial Performance Metrics - Organic growth was reported at -1%, contrasting with the estimated growth of 1.1% by analysts [4] - Net Sales in Protein Sciences amounted to $202.2 million, below the average estimate of $208.25 million, representing a year-over-year decline of -1.1% [4] - Net Sales in Diagnostics and Spatial Biology reached $79.5 million, slightly below the average estimate of $80.65 million, showing a year-over-year change of -4.4% [4] Stock Performance - Techne's shares have returned +3.2% over the past month, outperforming the Zacks S&P 500 composite, which saw a +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - Organic revenue declined 1% in Q1, primarily due to clinical stage timing from large customers in the cell therapy business and ongoing softness in biotech funding [4][19] - Adjusted EPS for the quarter was $0.42, flat year-over-year, while GAAP EPS increased to $0.24 from $0.21 in the prior year [18][19] - Total revenue for Q1 was $286.6 million, representing a 1% year-over-year decline on both an organic and reported basis [19] - Adjusted gross margin improved to 70.2%, up from 69.5% last year, driven by the exosome diagnostics divestiture and ongoing productivity initiatives [20] - Adjusted operating margin reached 29.9%, up 90 basis points year-over-year [20] Business Line Data and Key Metrics Changes - Protein sciences segment reported sales of $202.2 million, down 1% year-over-year, with organic revenue declining 3% [22] - Diagnostics and spatial biology segment sales were $79.5 million, down 4% year-over-year, but achieved 3% organic growth [22] - The protein analytical tools business showed notable strength from large pharma customers, contributing to organic growth [22] Market Data and Key Metrics Changes - Revenue from large pharma customers increased low double digits, while biotech spending continued to decline, resulting in high single-digit declines in Q1 [5][19] - North America experienced mid-single digit revenue decline, while Europe and Asia posted low single-digit growth [19][22] - China achieved its second consecutive quarter of growth, driven by strong performance in ProteinSimple analytical instruments and spatial biology portfolio [7][19] Company Strategy and Development Direction - The company is focused on productivity and cost management while investing in strategic growth pillars [5][17] - The acquisition of Wilson Wolf is expected to enhance the company's position in the cell therapy market, with plans to complete the acquisition by the end of calendar 2027 [9][10] - The company anticipates a return to positive organic growth in the second half of the fiscal year, driven by improving conditions in the biopharma sector and stabilization in U.S. academic markets [25][39] Management's Comments on Operating Environment and Future Outlook - Management noted that underlying market trends remain constructive, with early signs of stabilization in biotech activity levels [6][18] - The company expects Q2 organic growth to be consistent with Q1, reflecting continued strength in pharma and renewed growth in China [25] - Management expressed optimism about the recovery in biotech funding and the potential for lower interest rates to support investment levels in emerging biotech companies [6][35] Other Important Information - The company achieved an estimated 40% reduction in Scope 1 and 2 emissions during fiscal 2025, transitioning to 100% renewable electricity at its largest site [17] - The diagnostics business grew mid-single digits in Q1, supported by balanced performance across core diagnostic controls and kits [15] Q&A Session Summary Question: How long might the air pocket persist for GMP proteins? - Management indicated that the headwind from two large customers would be approximately 400 basis points in Q2, but they remain positive about the underlying recovery in the biotech markets [28][30] Question: Are growth plans for fiscal 2026 still low single-digit? - Management confirmed that plans remain unchanged, with a commitment to the cell therapy market and expectations for low single-digit growth for the year [30] Question: What is the outlook for the second half of the fiscal year? - Management expects a return to positive organic growth in the second half, driven by easing headwinds and improved market conditions [25][39] Question: Can you provide an update on Wilson Wolf? - Wilson Wolf had a flat quarter, but management remains optimistic about its potential to accelerate growth in the cell therapy market [43][44] Question: What are the assumptions for government shutdown impacts? - Management noted no significant changes in academic customer buying patterns due to the government shutdown, indicating stability in the academic market [52]

Techne (TECH) came out with quarterly earnings of $0.42 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.5 per share when it actually produced earnings of $0.53, delivering a surprise of +6%.Over the last four quarters, the company has surpassed consensus EPS estimates three times ...

Group 1 - The biotech firm Bio-Techne missed its first-quarter revenue estimates [1] - The company faced challenges due to sluggish demand for its products [1] - The soft biotech funding environment in China negatively impacted the company's performance [1]

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article emphasizes that users may face access issues if ad-blockers are enabled, suggesting the need to disable them for a better experience [1]

Kelderman added, "Our differentiated portfolio of advanced life science tools, reagents, and diagnostic products continues to enable breakthroughs in science and medicine. With our world-class team, sharpened strategic focus, innovation capabilities and sector-leading financial profile, Bio-Techne remains well positioned to deliver long-term value for all stakeholders." Conference Call Bio-Techne will host an earnings conference call today, November 5, 2025 at 8:00 a.m. CST. To listen, please dial 1-800-274 ...

Core Insights - Bio-Techne Corporation reported a 1% decrease in net sales for the first quarter of fiscal 2026, totaling $286.6 million, with organic revenue also down by 1% compared to the previous year [6][9][30] - The company experienced a 19% increase in GAAP operating income, reaching $47.7 million, and a GAAP EPS of $0.24, up from $0.21 in the same quarter last year [7][21] - Adjusted operating margin improved to 29.9%, reflecting ongoing productivity and cost containment initiatives [10][24] Financial Performance - Net sales decreased by 1% to $286.6 million, with organic revenue also down by 1%, influenced by a favorable foreign currency impact of 1% and an unfavorable impact from businesses held-for-sale [6][9] - GAAP operating income increased by 19% to $47.7 million, with an operating margin of 16.6%, up from 13.8% in the prior year [7][24] - Adjusted EPS remained stable at $0.42, while adjusted operating income rose to $84.2 million from $83.2 million [10][28] Segment Performance - The Protein Sciences segment reported net sales of $202.2 million, a decrease of 1% from $204.5 million in the prior year, with an operating margin of 38.4% [12][29] - The Diagnostics and Spatial Biology segment saw net sales of $79.5 million, down 4% from $83.2 million, but achieved organic revenue growth of 3% [13][29] - The overall operating income for the segments combined was $86.6 million, with a notable increase in the operating margin for the Diagnostics and Spatial Biology segment to 11.2% from 5.1% [31] Strategic Initiatives - The company completed the divestiture of its Exosome Diagnostics business to focus on non-CLIA based product lines, aligning with its growth strategy [9][10] - Bio-Techne's leadership expressed optimism regarding the stabilization of the US academic end market and continued strength from large pharmaceutical customers [3][9] - The company is positioned to leverage its differentiated portfolio of advanced life science tools and reagents to drive long-term value [3][10]

Core Insights - Bio-Techne Corporation and Nucleai presented pivotal data from the SECOMBIT clinical trial at the SITC 2025 Annual Meeting, highlighting the importance of spatial biology in immuno-oncology research [1][2] Study Overview - The SECOMBIT trial combined an immuno-oncology multiplex immunofluorescence panel with AI-driven multimodal biomarker analysis, profiling 42 pre-treatment biopsies from metastatic melanoma patients [2][5] - The study utilized Bio-Techne's COMET platform and Nucleai's multimodal spatial operating system to correlate immune cell interactions with clinical outcomes such as progression-free survival (PFS) and overall survival (OS) [2][5] Key Findings - The location and interaction of immune cells within tumors significantly influence treatment success, enabling better predictions of patient responses to therapies [4] - Specific immune activation markers were linked to improved outcomes across different treatment arms, indicating the potential of spatial biomarkers in clinical decision-making [6][4] Clinical Trial Data - The trial data demonstrated that Bio-Techne's and Nucleai's technologies can identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapy [5] - The study was recognized as one of the top 150 abstracts from over 1,200 submissions at the SITC 2025 [5] Availability at SITC 2025 - Bio-Techne's spatial biology portfolio, including the new ProximityScope assay, will be showcased at Booth 603, with visual data from the SECOMBIT study presented in Poster 528 [7] Company Background - Bio-Techne Corporation is a global life sciences company with over $1.2 billion in net sales for fiscal 2025, providing tools and reagents for research and clinical diagnostics [8] - Nucleai specializes in AI-powered multimodal spatial biology, integrating high-plex spatial proteomics and clinical data to develop precision medicine products [9]

Bio-Techne (NasdaqGS:TECH) FY 2025 Annual General Meeting October 30, 2025 09:00 AM ET Company ParticipantsShane Bohnen - General Counsel and Corporate SecretaryOperatorGood morning and welcome to the Bio-Techne Corporation Annual Meeting of Shareholders. I would now like to turn the conference call over to Shane Bohnen, General Counsel and Corporate Secretary of Bio-Techne. Please go ahead.Shane BohnenWelcome to our annual shareholders meeting. It is 8:00 A.M. Central Time on October 30th, 2025, and the me ...

Financial Data and Key Metrics Changes - The meeting confirmed that approximately 90% of shares were represented by proxy as of September 5, 2025, indicating strong shareholder engagement [2] - All proposals presented during the meeting, including the election of directors and the ratification of KPMG as the public accounting firm for the 2026 fiscal year, were passed [3] Business Line Data and Key Metrics Changes - No specific financial data or metrics related to individual business lines were discussed during the meeting [4] Market Data and Key Metrics Changes - No specific market data or metrics were provided during the meeting [4] Company Strategy and Development Direction - The company is focused on maintaining strong governance with the election of directors and the appointment of KPMG for auditing services, which reflects a commitment to transparency and accountability [3] Management Comments on Operating Environment and Future Outlook - There were no specific comments from management regarding the operating environment or future outlook during the meeting [4] Other Important Information - The meeting was attended by key executives including the CEO, CFO, and members of the Board of Directors, indicating a unified leadership presence [2] Q&A Session Summary - No questions were submitted by shareholders during the Q&A session, indicating either satisfaction with the information provided or a lack of engagement [4]